ZNTL Institutional Ownership
ZENTALIS PHARMACEUTICALS INC
Latest close $4.84 as of Aug 5, 2026
ZNTL institutional ownership at a glance
Follow ZENTALIS PHARMACEUTICALS INC institutional ownership through recent Schedule 13G and 13D filings. Compare reported shares, ownership percentages, filing dates, and changes in beneficial ownership over time.
Latest filing: BlackRock filed Initial Schedule 13G on Jul 30, 2026, reporting 3.7M shares and 12.00% beneficial ownership.
How to read Schedule 13 ownership changes
Schedule 13G/13D reports beneficial ownership at an observation date. “Accumulation” or “reduction” is inferred from changes in reported shares when available; it is not a list of individual trades or exact execution prices.
Form 13F rows are quarter-end holding context only and do not establish an exact entry date.
For more context, see how to read a Schedule 13G, filing date vs event date, or Schedule 13G vs Schedule 13D.
Institutional Research
This gauge summarizes recent agreement across tracked institutional activity.
1 reducing across 1 comparable institution.
The overall consensus is public. Detailed holder comparisons, breadth history, ownership charts, and filing-specific signal analysis remain part of Investor and Pro research.
Price context
52-week position is market context and does not change the institutional consensus score.
Tracked institutions
Public holder names and filing freshness. Detailed institution-by-institution analysis is locked.
Beneficial ownership filing history
Showing 3 of 5 filing(s) · 2 older require more history access| Holder | Observed / filed | Reported change | Shares | Ownership | Observation | Filing | Latest |
|---|---|---|---|---|---|---|---|
| BlackRock CIK0002012383 | Jun 30, 2026 observed Jul 30, 2026 filed · 30d Initial Schedule 13G | Initial Schedule 13G | 3.7M | 12.00% | $4.85 | $4.92 | $4.84 |
| Citadel Advisors CIK0001423053 | Sep 30, 2024 observed Nov 14, 2024 filed · 45d Schedule 13G amendment | Earliest Schedule 13G amendment found | 6 | 3.90% | $3.68 | $3.95 | $4.84 |
| BlackRock CIK0002012383 | Sep 30, 2024 quarter end Nov 13, 2024 filed Form 13F quarter-end evidence | Earlier Form 13F quarter-end holding Quarter-end holding evidence; no ownership percentage or signal. | 4.8M | $3.68 | $4.84 |
Related research
Compare ZNTL with other securities showing similar institutional activity or recent accumulation across several tracked institutions.